Oculis director Lionel Carnot resigns from board

Geraldine O’Keeffe will chair the Remuneration Committee, while Swiss law permits the Board vacancy to be filled only at a future general meeting.

Rhea-AI Filing Summary

Oculis Holding AG (OCS) announced that director Lionel Carnot’s resignation from the Board of Directors is effective September 30, 2026. Carnot has served on the Board since 2017. Oculis said the departure is a personal decision and is not the result of a disagreement about the company’s operations, policies or practices. After the resignation, the Board will consist of eight members. Geraldine O’Keeffe will chair the Remuneration Committee, with Gregory Perry and Robert Warner as members. Under Swiss law, the vacancy may be filled only at a future annual or special general meeting. Oculis said it will begin identifying a successor and provide updates as appropriate.

Key Figures

Board members after resignation: 8 members Carnot’s Board service began: 2017 Resignation effective date: September 30, 2026

3 metrics

Board members after resignation 8 members Following Lionel Carnot’s resignation

Carnot’s Board service began 2017 He had served since 2017

Resignation effective date September 30, 2026 Lionel Carnot’s Board resignation

Key Terms

Remuneration Committee, registrational trial, genotype-based approach, optic neuropathies

4 terms

Remuneration Committee technical

"the Remuneration Committee, of which Mr. Lionel served as chair"

A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.

registrational trial medical

"Licaminlimab is a novel, topical anti-TNFα in a registrational trial"

A registrational trial is the large, definitive clinical study designed to provide the evidence regulators need to decide whether a new drug or medical product can be approved for sale. Think of it as the final exam for a treatment: passing it can unlock widespread market access and potential revenues, while failing it can sharply reduce a product’s commercial prospects and raise investment risk.

genotype-based approach medical

"being developed with a genotype-based approach for treating patients with dry eye disease"

optic neuropathies medical

"treatment of optic neuropathies, including optic neuritis"

Optic neuropathies are conditions in which the optic nerve—the cable that carries visual information from the eye to the brain—is damaged, causing reduced vision, blind spots, or color loss. For investors, these disorders matter because they create markets for drugs, devices, diagnostics and surgeries, influence regulatory approvals and reimbursement, and can affect a company's clinical trial prospects and potential revenues much like a critical fault in an electrical cable drives demand for repairs and replacements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is Lionel Carnot leaving Oculis’ board?

Carnot said he is stepping down to focus on other commitments as Oculis enters its next stage of growth. The company described the departure as a personal decision and said it is not the result of a disagreement about its operations, policies or practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 05:03 PM Accepted by SEC EDGAR 09/30/2026 - 05:02 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September 2026

(Commission File No. 001-41636)

Oculis Holding AG

(Translation of registrant's name into English)

Bahnhofstrasse 20

CH-6300

Zug, Switzerland

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 30, 2026, Oculis Holding AG announced the resignation of Lionel Carnot from the Board of Directors. The press release is furnished hereto as Exhibit 99.1.

EXHIBIT INDEX

Exhibit		Description
99.1		Press Release dated September 30, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

				OCULIS HOLDING AG
Date: September 30, 2026				By:
						Sylvia Cheung Chief Financial Officer

Oculis Announces Resignation of Lionel Carnot from Board of Directors

ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.

Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the Board and the entire Oculis team, we wish to extend our sincere gratitude to Lionel for his invaluable service, leadership and guidance over nearly a decade, covering a transformative period for Oculis, where it evolved from a private startup company to a publicly listed late-stage biopharmaceutical company. His contributions to the Board and Oculis have been instrumental in our growth and evolution to become an emerging leader in neuro-ophthalmology.”

Lionel Carnot remarked: “It has been a privilege to work alongside Oculis’ talented and dedicated team committed to addressing significant unmet medical needs and advance innovative solutions for patients suffering from ophthalmic and neuro-ophthalmic diseases. As the Company enters its next stage of growth, this is a timely point for me to step down and focus on other commitments. As an investor, I remain confident in the potential of Oculis’ pipeline and look forward to the Company achieving important milestones in the years ahead.”

Mr. Carnot’s departure is purely a personal decision and is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. Following the resignation, the Board will consist of eight members and the Remuneration Committee, of which Mr. Lionel served as chair, will consist of Geraldine O’Keeffe as chair and Gregory Perry and Robert Warner as members. Pursuant to Swiss law, the vacancy on the Board resulting from Mr. Carnot’s resignation may only be filled at a future annual or special general meeting. Oculis will begin identifying a successor for Mr. Carnot and will provide updates as appropriate.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit:

Oculis Contact

Ms. Sylvia Cheung, CFO

sylvia.cheung@oculis.com

Investor Relations

LifeSci Advisors

Corey Davis, Ph.D.

cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 17.6 KB